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The relationship between the degree of glycaemic
control and mortality remains an important topic of
discussion.
Aim






A total of 1145 patients with type 2 diabetes were
enrolled in the Zwolle Outpatient Diabetes project
Integrating Available Care (ZODIAC) in 1998. Their
survival status was recorded in September 2004.
Mortality ratios were calculated using standardised
mortality ratios (SMRs). Associations between
haemoglobin A1c (HbA1c) levels and mortality were
studied with a Cox proportional hazard model. HbA1c
levels were studied as continuous and as categorical
variables.
Results
A total of 335 patients died after a median follow-up
period of 5.8 years. The SMR (95% confidence interval
[CI]) for total mortality was 1.86 (95% CI = 1.66 to 2.06)
and 2.24 (95% CI = 1.91 to 2.61) for cardiovascular
mortality. For each 1% increase in HbA1c there was a
21% increase in the hazard ratio for total mortality.
When compared with the target HbA1c group (HbA1c
6.5–7%), the group with very poor glycaemic control
(HbA1c >9%) had a hazard ratio of 2.21 (95% CI =
1.42 to 3.42) for total mortality. The group with normal
glycaemic control (HbA1c <6.5%) had a hazard ratio of
1.00 (95% CI = 0.46 to 2.19) for total mortality.
Conclusion
HbA1c level was associated with mortality and this
effect seemed largely attributable to patients who were
in really poor glycaemic control. The absence of
differences in mortality in the groups with lower HbA1c
levels supports the position that there is no basis for
continually decreasing the therapeutic target HbA1c
level in patients with type 2 diabetes mellitus.
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INTRODUCTION
Patients with type 2 diabetes mellitus have a two- to
fivefold increase in risk for developing
cardiovascular disease compared to people without
diabetes.1,2 Between 50% and 75% of all deaths
seen in patients with type 2 diabetes are related to
cardiovascular complications.3 Since this excess
risk is only partially explained by traditional risk
factors, such as obesity, dyslipidaemia, and
hypertension, type 2 diabetes is often considered an
independent risk factor for cardiovascular morbidity
and mortality.
A strong body of evidence links chronic
hyperglycaemia to microvascular complications. A
meta-analysis of observational studies suggests
that hyperglycaemia is also associated with an
increased risk for cardiovascular mortality in
patients with type 2 diabetes.4 In the UK Prospective
Diabetes Study (UKPDS), a continuous relationship
was found between glycosylated haemoglobin
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(HbA1c) levels and rates of macrovascular
complications. For every 1% decrease in HbA1c
level, investigators estimated a 14% decrease in
myocardial infarction, a 12% decrease in stroke, and
a 14% reduction in all-cause mortality.5 Results from
a meta-analysis of all the randomised trials in which
glycaemic control and its relationship to
macrovascular risk were studied in patients with
both type 1 and type 2 diabetes, showed that
glucose lowering itself reduces cardiovascular risk.6
Three recently performed studies have
investigated the role of intensive glycaemic
control.7–9 The Action to Control Cardiovascular Risk
in Diabetes (ACCORD) trial showed a significantly
higher mortality rate in the intensive treatment group
compared to the standard glucose-lowering therapy
group.7 The two other trials, the Action in Diabetes
and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation (ADVANCE)
trial and the Veterans Affairs Diabetes Trial (VADT),
found no effect of intensive glycaemic control on the
occurrence of major macrovascular events or all-
cause mortality compared to the control group.8,9
The post-trial study from the UKPDS suggested that
the effects on mortality of a more intensive strategy
to control blood glucose levels in patients with
newly diagnosed type 2 diabetes were sustained for
up to 10 years after the cessation of randomised
interventions.10 The major difference between the
three recently performed studies and the post-trial
study from the UKPDS is that in the UKPDS only
patients with newly diagnosed type 2 diabetes were
included.
In light of these results, the goal of this study was
to investigate the relationship between glycaemic
control (as indicated by HbA1c level) and mortality in
patients with type 2 diabetes, in a prospective
observational setting.
METHOD
In 1998, in the Zwolle region (the Netherlands), a
large shared-care diabetes project was initiated, the
Zwolle Outpatient Diabetes project Integrating
Available Care (ZODIAC). In this project, GPs were
assisted in their care of patients with type 2
diabetes by hospital-based nurses specialising in
diabetes. As part of this project, the patients with
type 2 diabetes in 32 primary care practices
consulted (and still consult) these diabetes
specialist nurses annually. Patients with a very short
life expectancy (including patients with active
cancer) or insufficient cognitive abilities were
excluded. During the first year of the project, 1664
subjects with type 2 diabetes were identified in
these practices. Patients being treated by
specialists in internal medicine (n = 338) were
excluded. Fifty-seven patients were excluded by
their GPs due to an estimated very short life-
expectancy or insufficient cognitive abilities. Of the
1269 patients who were invited to participate, 1149
(91%) agreed. Four patients were excluded due to
insufficient baseline data. Details of the ZODIAC
study have been published previously.11
Baseline data were collected in 1998 and 1999
and involved a full medical history, including the
presence or absence of macrovascular
complications, medication use, and tobacco
consumption. Laboratory and physical assessment
data were collected on a yearly basis and included
lipid profile, creatinine, (micro)albuminuria, blood
pressure, weight, and height. HbA1c was measured
first at baseline and annually thereafter. An updated
mean of annually measured HbA1c was calculated for
each individual from baseline to the end of the
follow-up period. This is in accordance with the
technique used in the UKPDS 35.5 For example, at
2 years the updated mean is calculated using the
average of the baseline, 1-year, and 2-year values,
and at 4 years, the updated mean is the average of
the baseline, 1-year, 2-year, 3-year, and 4-year
values.
Records maintained by the hospital and the GPs
were used to obtain cause of death information for
the patients who died during the study. The causes
of death were coded according to The International
Classification of Diseases, 9th Revision (ICD-9). To
study the incidence of cardiovascular-related
mortality, standardised mortality ratios (SMRs) were
calculated using general mortality reference rates
from the eastern part of the Netherlands.12 A Cox
proportional hazard model was then used to assess
the association between updated mean HbA1c levels
and mortality (all-cause and cardiovascular). The
updated mean value was included as a time-
dependent covariate to evaluate glycaemic control
during follow-up. Using updated mean HbA1c levels
as a continuous variable, models were developed
and applied to determine the all-cause mortality risk
associated with a 1% reduction in the HbA1c level.
Separate analyses were done for HbA1c as a
grouped variable (<6.5%, 6.5–7%, 7–8%, 8–9%,
How this fits in
Three recent randomised studies (the ACCORD, ADVANCE, and VADT trials)
showed that a low haemoglobin A1c (HbA1c) target level does not result in
decreased mortality. In this study, HbA1c was a significant predictor for mortality.
This effect seems largely attributable to poor glycaemic control. The study data
suggest that for patients with moderate glycaemic control, it may be better to
focus on other risk factors than to keep on lowering the target values for HbA1c.
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and ≥9%), and the therapeutic target range for HbA1c
(between 6.5% and 7%) was used as a reference.
The following variables were included in the models
as possible confounders: age, sex, smoking (never,
previous, and current), duration of diabetes,
creatinine, body mass index, systolic blood
pressure, total cholesterol-HDL (high-density
lipoprotein) ratio, macrovascular complications
(yes/no), use of statins (yes/no), insulin use (yes/no),
and albuminuria (yes/no).
RESULTS
The baseline characteristics of the study population
are shown in Table 1. A total of 335 (31%) patients
died during a median follow-up of 5.8 years. Date and
cause of death could not be traced in 6 and 20
patients, respectively. Out of the 315 known causes
of death, 51% (n = 161) were attributable to
cardiovascular disease, 21% (n = 70) to malignancies,
and 10% (n = 34) to respiratory diseases.
The SMR (95% confidence interval [CI]) for total
mortality was 1.86 (95% CI = 1.66 to 2.06) and 2.21
(95% CI = 1.42 to 3.42) for cardiovascular mortality.
The hazard ratio (HR) for the updated HbA1c mean
(continuous variable) was 1.21 (95% CI = 1.07 to
1.36) for all-cause mortality.
HRs for the updated HbA1c mean in the categories
<6.5% (n = 228), 7–8% (n = 318), 8–9% (n = 208),
and ≥9% (n = 144) were 1.11 (95% CI = 0.71 to
1.74), 1.40 (95% CI = 0.99 to 1.97), 1.43 (95% CI =
0.97 to 2.10), and 2.26 (95% CI = 1.39 to 3.67)
respectively compared to HbA1c 6.5–7% (n = 245)
for all-cause mortality (Figure 1). HRs for the
updated HbA1c mean in the categories <6.5% (n =
228), 7–8% (n = 318), 8–9% (n = 208), and ≥9% (n
= 144) were 0.94 (95% CI = 0.47 to 1.91), 1.40 (95%
CI = 0.84 to 2.31), 1.71 (95% CI = 0.99 to 2.96), and
3.13 (95% CI = 1.62 to 6.05) respectively, compared
to HbA1c 6.5–7% (n = 245) for cardiovascular
mortality (Figure 2).
DISCUSSION
Summary of main findings
HbA1c seems to be a predictor for mortality in type 2
diabetes mellitus, but whether this predictive value
translates to causality is unknown. In the present
study cohort, the increased mortality risk, corrected
for risk factors including diabetes duration, seems
largely attributable to those patients with poor
glycaemic control.
Patients with an average HbA1c ≥9% have a 2.26
higher total mortality risk and a 3.13 higher
cardiovascular mortality risk compared to the group
with an HbA1c at the current therapeutic target level
(6.5–7%). Patients with an average HbA1c <9% did
not have significantly different risks for total and
cardiovascular mortality. A HbA1c level <6.5% does
not seem to change cardiovascular and all-cause
mortality risks when compared with the normal
target range of 6.5–7%.
There are several plausible physiological
explanations for the effect of chronically elevated
glucose levels on cardiovascular disease risk.
Total Deceased patients Patients that
Characteristics (n = 1145) (n = 335) survived (n = 810)
Age, years 68.7 76.5 65.5
(±11.5) (±8.7) (±11.0)a
Female, % 54.3 58.8 57.5
Diabetes duration, years 7.7 9.2 7.1
(±7.5) (±8.5) (±7.0)a
Smoking, %
Never 50.4 51.9 49.8
Former smoker 30.6 31.6 30.1
Current smoker 18.1 14.9 19.4
BMI, kg/m² 28.9 28.3 29.2
(±4.8) (±5.0) (±4.7)b
Systolic blood pressure, mmHg 155.1 154.0 154.3
(±25) (±27) (±24)
HbA1c, % 7.5 7.6 7.5
(±1.3) (±1.3) (±1.2)c
Creatinine clearance, ml/min 63.2 51.5 68.1
(±20.0) (±16.7) (±19.2)a
Total cholesterol/HDL ratio 5.3 5.2 5.2
(±1.60) (±1.7) (±1.5)
LDL cholesterol, mmol/l 3.4 3.3 3.4
(±1.0) (±1.0) (±1.0)
Statin use, % 11.2 10.2 12.1
Insulin use, % 15.4 21.2 12.3a
Microalbuminuria, % 41.8 55.3 36.6a
Macroalbuminuria, % 5.5 7.9 4.5c
Macrovascular complications, % 61.4 77.9 54.5a
HDL = high-density lipoprotein. LDL = low-density lipoprotein. Data are means (± standard
deviation) or %. aP<0.001. bP<0.01. cP<0.05.






























Glucose can react with various proteins to form
advanced glycation end-products, which may
contribute to long-term complications of diabetes,
plaque formation, and atherosclerosis. These effects
are gradual and likely to be cumulative.13
Strengths and limitations of the study
Because of the observational nature of the study,
the associations found do not imply causality. The
study population itself presents other limitations. A
patient population of 1145 is rather small. Second, it
is comprised of patients treated in primary health
care, and therefore might represent a population
with less overall risk, since many subjects with more
complicated disease will be treated in secondary
care in the Netherlands. However, approximately
80% of the patients with type 2 diabetes are treated
at the primary healthcare level, allowing the study
conclusions to be applicable to a majority of
patients with type 2 diabetes.
Comparison with existing literature
The results of this study agree with those reported in
the ACCORD,7 ADVANCE,8 and VADT9 studies, that
a low HbA1c therapeutic target level does not result
in decreased mortality. In fact, in the ACCORD trial,
increased mortality was seen in the intensive
treatment group.7 It is possible that the use of
multiple types of medications in an attempt to
achieve normal blood glucose levels in patients with
longstanding type 2 diabetes results in increased
side-effects, and perhaps also increased mortality.
Implications for clinical practice
The results of this observational study show that
there is not much difference in mortality risk, as long
as HbA1c levels are below 9%. Postponing death is
not the only treatment goal in patients with type 2
diabetes, and the prevention of microvascular
complications with strict metabolic control should
also be a priority. The study data suggest that, in
order to increase the life expectancy in these
patients, glycaemic control is important in patients
with poor control (HbA1c >9%). For patients with
moderate glycaemic control and longstanding
diabetes, it may be better to focus on other risk
factors, such as smoking, high blood pressure, and
lipid profile disturbances, than to aim for
increasingly lower therapeutic target values for
HbA1c.
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Figure 2. Hazard ratio’s
for cardiovascular
mortality for five HbA1c
categories, reference
category is 6.5–7.0.
